Scarica l'app Stockscreener
52.97
3.34%
-1.83
Dopo l'orario di chiusura:
52.97
Precedente Chiudi:
$54.80
Aprire:
$53.35
Volume 24 ore:
580.50K
Relative Volume:
1.20
Capitalizzazione di mercato:
$3.40B
Reddito:
$112.53M
Utile/perdita netta:
$-258.91M
Rapporto P/E:
-12.23
EPS:
-4.33
Flusso di cassa netto:
$-124.42M
1 W Prestazione:
-1.40%
1M Prestazione:
-3.53%
6M Prestazione:
+1.11%
1 anno Prestazione:
+22.25%
Intervallo 1D:
$51.53
$53.41
Intervallo di 1 settimana:
$51.53
$55.21
Portata 52W:
$35.17
$68.58
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Nome
Rhythm Pharmaceuticals Inc
Settore
Industria
Telefono
857-264-4280
Indirizzo
222 BERKELEY STREET, BOSTON, MA
Confronta RYTM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
52.97 | 3.40B | 112.53M | -258.91M | -124.42M | -4.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-05 | Ripresa | Stifel | Buy |
| 2025-01-02 | Iniziato | Jefferies | Buy |
| 2024-12-20 | Iniziato | Oppenheimer | Outperform |
| 2024-10-21 | Iniziato | Guggenheim | Buy |
| 2024-09-18 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-17 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-05-08 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-01-18 | Ripresa | Canaccord Genuity | Buy |
| 2022-08-08 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-08-05 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-06-17 | Reiterato | Needham | Buy |
| 2022-03-02 | Ripresa | Stifel | Buy |
| 2022-02-17 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | Ripresa | Goldman | Neutral |
| 2021-08-04 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-08-04 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-01-08 | Iniziato | Goldman | Sell |
| 2019-07-12 | Aggiornamento | Stifel | Hold → Buy |
| 2019-07-08 | Iniziato | Canaccord Genuity | Buy |
| 2019-03-13 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-09-07 | Ripresa | Morgan Stanley | Overweight |
| 2018-06-25 | Reiterato | Needham | Buy |
| 2018-06-15 | Reiterato | Needham | Buy |
| 2017-10-30 | Iniziato | BofA/Merrill | Buy |
| 2017-10-30 | Iniziato | Needham | Buy |
Mostra tutto
Rhythm Pharmaceuticals Inc Borsa (RYTM) Ultime notizie
When Will Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Breakeven? - simplywall.st
Rhythm Pharma ends RareStone licensing deal in China - MSN
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Equities Analysts Offer Predictions for RYTM Q1 Earnings - Defense World
Q2 Earnings Estimate for RYTM Issued By HC Wainwright - Defense World
Swiss National Bank Has $5.05 Million Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Given Buy Rating at HC Wainwright - Defense World
Rhythm Pharmaceuticals corporate controller sells shares for $18,655 By Investing.com - Investing.com Australia
Rhythm Pharmaceuticals corporate controller sells shares for $18,655 - Investing.com India
Analyst Expectations For Rhythm Pharmaceuticals's Future - Benzinga
Is Rhythm Pharmaceuticals (RYTM) a Worst High-Risk High-Reward Growth Stock to Buy? - MSN
(RYTM) Proactive Strategies - news.stocktradersdaily.com
Rhythm Pharma stock down as licensing deal ends (RYTM:NASDAQ) - Seeking Alpha
Victory Capital Management Inc. Reduces Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals regains rights to obesity drug in China By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd. - MarketScreener
Rhythm Pharmaceuticals regains rights to obesity drug in China - Investing.com India
Rhythm Pharmaceuticals Reacquires Licensing Rights to - GlobeNewswire
Strategic Win: Rhythm Pharmaceuticals Reclaims IMCIVREE Rights in China, Strengthens Global Position - StockTitan
Rhythm Pharmaceuticals Announces Orphan Drug Designation - GlobeNewswire
Rhythm Pharmaceuticals receives orphan drug status in Japan By Investing.com - Investing.com Australia
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted To Setmelanotide For Treatment Of Hypothalamic Obesity In Japan - Marketscreener.com
Rhythm Pharmaceuticals receives orphan drug status in Japan - Investing.com
Rhythm Pharmaceuticals Receives Orphan-Drug Designation in Japan for Obesity Treatment - MarketWatch
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan - The Manila Times
Breakthrough for Rare Obesity: Rhythm's Drug Wins Special Status in Japan - StockTitan
Rhythm Pharmaceuticals EVP sells shares worth $3.86 million By Investing.com - Investing.com South Africa
Charles Schwab Investment Management Inc. Has $24.65 Million Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Given New $66.00 Price Target at Needham & Company LLC - Defense World
Rhythm Pharmaceuticals EVP sells shares worth $3.86 million - Investing.com India
Needham raises Rhythm Pharma stock target to $66, maintains buy By Investing.com - Investing.com UK
Rhythm Pharmaceuticals and Raymond A. Wood Foundation Launch Research Collaboration on Fatigue in Craniopharyngioma Patients - Nasdaq
Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration - GlobeNewswire
Bank of New York Mellon Corp Sells 680 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Insider Sell Alert: EVP, Head of North America Jennifer Lee Sells Shares of Rhythm Pharmaceuticals Inc (RYTM) - GuruFocus.com
How To Trade (RYTM) - Stock Traders Daily
SBI Securities Co. Ltd. Invests $37,000 in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Stifel maintains Buy on Rhythm Pharmaceuticals, $78 target By Investing.com - Investing.com Canada
Stifel maintains Buy on Rhythm Pharmaceuticals, $78 target - Investing.com India
Reviewing Wave Life Sciences (NASDAQ:WVE) & Rhythm Pharmaceuticals (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Earns Overweight Rating from Morgan Stanley - Defense World
Assessing Rhythm Pharmaceuticals: Insights From 10 Financial Analysts - Benzinga
Promising Outlook for Rhythm Pharmaceuticals: Buy Rating Backed by Positive Phase 3 Study Expectations and Market Potential - TipRanks
Stifel Nicolaus Begins Coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) - Defense World
Analysts Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) PT at $68.27 - Defense World
Rhythm Pharmaceuticals Inc Azioni (RYTM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.05%
1.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):